Evidence map›Paper›PMID 40757253›Full record

Observational studyGlobal heart2025

Long COVID Syndrome, Mortality and Morbidity in Patients Hospitalized with COVID-19 From 16 Countries: The World Heart Federation Global COVID-19 Study.

Karen Sliwa, Kavita Singh, Kalyani Nikhare, Dimple Kondal, Lana Raspail, Meetushi Jain, Shahin Akter, Shamim Hayder Talukder, Toru Kato, Silvia Bertagnolio and 7 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Global heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Cellular Metabolic Signatures of Long COVID-19.Infectious disease reports · 2026
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Karen SliwaCape Heart Institute, Department of Medicine and Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, South Africa.ORCID 0000-0002-8272-0911
Kavita SinghPublic Health Foundation of India, New Delhi, India.ORCID 0000-0003-4330-666X
Kalyani NikharePublic Health Foundation of India, New Delhi, India.ORCID 0000-0002-7895-3333
Dimple KondalCentre for Chronic Disease Control, New Delhi, India.ORCID 0000-0002-1417-9510
Lana RaspailWorld Heart Federation, Geneva, Switzerland.
Meetushi JainPublic Health Foundation of India, New Delhi, India.ORCID 0009-0001-6723-849X
Shahin AkterEminence, Bangladesh.
Shamim Hayder TalukderEminence, Bangladesh.ORCID 0000-0003-0308-2817
Toru KatoNHO Tochigi Medical Center, Japan.ORCID 0000-0002-1564-8681
Silvia BertagnolioWorld Health Organization, Geneva, Switzerland.ORCID 0000-0001-8416-2581
Jamie RylanceWorld Health Organization, Geneva, Switzerland.ORCID 0000-0002-2323-3611
Amitava BanerjeeUniversity College London, United Kingdom.ORCID 0000-0001-8741-3411
Jagat NarulaUniversity of Texas Health Science Center, Houston, United States of America.ORCID 0000-0002-0979-4674
Daniel PineiroUniversity of Buenos Aires, Argentina.ORCID 0000-0002-2509-2445
Pablo PerelWorld Heart Federation, Geneva, Switzerland.ORCID 0000-0002-2342-301X
Dorairaj PrabhakaranWorld Heart Federation, Geneva, Switzerland.ORCID 0000-0002-3172-834X
WHF COVID-19 Long Study Collaboration

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: Long-term adverse consequences of the COVID-19 infection affect many organ systems, which requires comprehensive understanding of the disease burden and determinants of persistent long COVID-19 symptoms in diverse population. However, data on long COVID complications are sparse, particularly from low- and middle-income countries (LMICs). The World Heart Federation (WHF) global study assessed the incidence of vascular complications, persistent long COVID symptoms and factors associated with mortality and major adverse cardiovascular events (MACE) among patients with COVID-19 up to one year after hospitalization. Methods: We recruited a total of 2535 patients hospitalized with COVID-19 and followed up to one-year post-hospital discharge. We collected data on long COVID symptoms, quality of life, and clinical outcomes, including new onset diseases, MACE, and mortality at 1-, 3-, 6-, and 9-12 months post-discharge. Descriptive and generalized estimating equation (GEE) regression analysis was performed to assess the factors associated with mortality and MACE. Findings: The majority of participants were recruited from LMICs (64%) and male (56%) with a mean (SD) age of 59.5 (20.0) years. Among those tested for COVID-19 strain (52%), Omicron strain was the most prevalent (98%). The follow-up rate at one year was 90%. Over half of the participants (56%) reported experiencing at least one major long COVID symptom (fatigue, breathlessness, anxiety, chest pain, and palpitations) at 1-month, and one-quarter participants reported persistent long COVID symptoms at 9-12 months. On the EQ-5D scale, 49% reported difficulties in usual activities, 33% reported anxiety/depression, and 23% reported problems in mobility within the first 6 months. The most frequent new-onset illnesses were pulmonary embolism (8%), kidney disease (4%), and hypertension (3%). The cumulative all-cause mortality rate was 15% (n = 382) at one-year post-discharge. Long COVID symptoms were more common among females, individuals with pre-existing comorbidities, and those with more severe acute illness. Age, obesity, ICU admission, and underlying cardiovascular or pulmonary disease were associated with increased risk of mortality and MACE. Conclusion: The study showed a substantial burden of mortality and morbidity, and a quarter of patients reported at least one persistent long COVID symptom after one year. Our findings underscore the need for early identification and management of long COVID symptoms in LMICs.

Indexed as

Cardiovascular DiseasesCOVID-19HospitalizationPost-Acute COVID-19 SyndromeAgedFemaleGlobal HealthHumansIncidenceMaleMiddle AgedMorbidityQuality of LifeSARS-CoV-2cardiovascular diseasecohortcoronavirusCOVID-19registrysurvey

Identifiers

PMID40757253
PMCPMC12315686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.